江苏吉贝尔药业股份有限公司 章 程 二〇二四年九月 | A | | --- | | 第一章 总 | 则 1 | | --- | --- | | | 第二章 经营宗旨和范围 2 | | | 第一节 股份发行 2 | | | 第二节 股份增减和回购 3 | | | 第三节 股份转让 4 | | 第四章 | 股东和股东大会 5 | | 第一节 | 股东 5 | | | 第二节 股东大会的一般规定 7 | | 第三节 | 股东大会的召集 11 | | 第四节 | 股东大会的提案与通知 12 | | 第五节 | 股东大会的召开 14 | | 第六节 | 股东大会的表决和决议 16 | | 第五章 | 董事会 20 | | 第一节 | 董事 20 | | 第二节 | 董事会 23 | | 第六章 | 总经理及其他高级管理人员 28 | | 第七章 | 监事会 29 | | 第一节 | 监事 29 | | 第二节 | 监事会 30 | | 第八章 | 财务会计制度、利润分配和审计 32 | | 第一节 | 财务会计制度 32 | | 第二节 | 内部审计 36 | | 第三节 | 会计师事务所的聘任 36 | | 第九章 ...

Group 1: Company Overview - Jiangsu Jibeier Pharmaceutical Co., Ltd. is the only company producing Likujun tablets domestically and internationally, establishing a significant market position in the leukocyte-promoting drug sector [2][3]. - The company has developed a robust R&D platform focusing on compound formulations, deuterated drugs, and liposome drug technologies, leading to a pipeline of innovative drugs [6]. Group 2: Product Highlights - Likujun tablets are primarily used for preventing and treating leukopenia and thrombocytopenia, showing significant efficacy in patients undergoing radiation and chemotherapy [3][5]. - The raw material quality of Likujun has been enhanced to over 99% after systematic secondary development, ensuring product safety and clinical efficacy [4]. Group 3: Market Performance - In the first half of 2024, sales revenue for Niqunlor tablets reached 65.82 million yuan, representing a year-on-year increase of 90.03% [5]. - The market for Niqunlor tablets, which target hypertension with concurrent tachycardia, is substantial, with over one-third of hypertension patients also experiencing elevated heart rates [5]. Group 4: Future Prospects - The company is actively expanding the application of Likujun tablets in oncology, having been included as a recommended medication for malignant tumors in a clinical path book published in May 2022 [5]. - Ongoing clinical trials for new drugs JJH201501 (antidepressant) and JJH201601 (anticancer) are progressing, with JJH201501 in Phase III trials and JJH201601 in Phase I trials [6].

证券代码：688566 证券简称：吉贝尔 公告编号：2024-052 本次股票上市流通总数为 2,900,000 股。 本次股票上市流通日期为 2024 年 9 月 20 日。 一、本次限制性股票归属的决策程序及相关信息披露 1、2021 年 8 月 6 日，公司召开第三届董事会第七次会议，审议通过了《公司 2021 年限制性股票激励计划（草案）及摘要》《公司 2021 年限制性股票激励计划 实施考核管理办法》《关于提请股东大会授权董事会办理股权激励相关事宜的议案》 等议案，公司独立董事就本次激励计划相关事项发表了明确同意的独立意见。 同日，公司召开第三届监事会第五次会议，审议通过了《公司 2021 年限制性 股票激励计划（草案）及摘要》《公司 2021 年限制性股票激励计划实施考核管理 办法》《关于核实<公司 2021 年限制性股票激励计划激励对象名单>的议案》，公司 监事会对本次激励计划的相关事项进行核实并出具了相关核查意见。 江苏吉贝尔药业股份有限公司 关于 2021 年限制性股票激励计划第三个归属期 归属结果暨股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2024-051 重要内容提示： 会议线上交流时间：2024 年 9 月 24 日（星期二）下午 15:00-16:00 会议召开方式：线上文字互动 线 上 文 字 互 动 平 台 ： 东 方 财 富 路 演 平 台 （ 网址： http://roadshow.eastmoney.com/luyan/4527751） 投资者可于 2024 年 9 月 23 日（星期一）16:00 前通过邮件、电话等形式 将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普 遍关注的问题进行回答。 江苏吉贝尔药业股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （三） 线 上 文 字 互 动 平 台 ： 东 方 财 富 路 演 平 台 （ 网址： http://roadshow.eastmoney.com/luyan/4527751） 江苏吉贝尔药业股份有限公司（以下简称"公司"）已于 2024 年 8 月 30 日在 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [1][4] Core Views - The company's profitability is improving, with a focus on the orderly advancement of innovative drug clinical trials [2][3] - In the first half of 2024, the company achieved revenue of 434 million yuan, a year-on-year increase of 3.55%, and a net profit attributable to the parent company of 122 million yuan, a year-on-year increase of 26.74% [2] - The company is advancing its innovative drug pipeline, including the antidepressant JJH201501, which is currently in Phase III clinical trials, and the anti-tumor drug JJH201601, which is undergoing Phase I clinical trials [3] Financial Performance Summary - In the first half of 2024, the operating cost was 44.9 million yuan, a decrease of 3.36% year-on-year, while sales expenses were 197 million yuan, down 1.70% year-on-year [3] - The company expects revenue growth rates of 17.95%, 21.34%, and 21.38% for 2024-2026, with net profit growth rates of 21.88%, 24.23%, and 23.47% for the same period [4] - The earnings per share (EPS) are projected to be 1.36 yuan, 1.69 yuan, and 2.08 yuan for 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (P/E) ratios of 15.16, 12.20, and 9.88 [4]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - In the first half of 2024, the company achieved total revenue of 434 million yuan (+3.55% year-on-year) and a net profit attributable to shareholders of 122 million yuan (+26.74%) [2] - The second quarter of 2024 saw total revenue of 239 million yuan (-5.54%) and a net profit of 69 million yuan (+19.30%) [2] - The high growth of the drug Niquinol tablets is noted, while the growth of Licorice tablets has slightly decreased due to a high base effect from the previous year [2] - The company’s gross profit margin improved to 89.65% (+0.74 percentage points) and net profit margin to 28.10% (+5.16 percentage points) in the first half of 2024 [2] - The report forecasts net profits of 270 million yuan, 336 million yuan, and 424 million yuan for 2024, 2025, and 2026 respectively, with corresponding P/E ratios of 15, 12, and 9 times [2] Financial Performance Summary - Total revenue for 2022 was 654.73 million yuan, increasing to an estimated 1,004.01 million yuan in 2024, representing a year-on-year growth of 16.62% [1] - Net profit attributable to shareholders was 154.67 million yuan in 2022, projected to reach 269.66 million yuan in 2024, reflecting a growth of 23.08% [1] - The latest diluted EPS is expected to be 1.37 yuan per share in 2024, up from 1.11 yuan in 2023 [1] Expense and Profitability Analysis - The sales expense ratio decreased to 45.39% in the first half of 2024, indicating a reduction in promotional activities [2] - R&D expense ratio also declined to 4.01% due to the capitalization of some R&D costs as new drugs enter the clinical phase [2] - The company is expected to continue optimizing sales and reducing expenses, which may lead to further profit margin improvements [2]

Financial Performance - In the first half of 2024, the company achieved operating revenue of 433.66 million CNY, a year-on-year increase of 3.55% [3] - The net profit attributable to shareholders was 122.01 million CNY, reflecting a year-on-year growth of 26.74% [3] - As of June 30, 2024, total assets amounted to 2.48 billion CNY, up 12.16% year-on-year, while net assets attributable to shareholders reached 2.17 billion CNY, increasing by 13.88% [3] Product Sales - The sales revenue for the main products in the first half of 2024 included: - Likujun tablets: 308.28 million CNY - Nigulol tablets: 65.82 million CNY - Yupingfeng capsules: 20.16 million CNY - Other products: 39.40 million CNY [3] - The sales of Nigulol tablets grew by 90.03% year-on-year, indicating effective promotion and market acceptance [4] Market Position and Product Advantages - Nigulol tablets are positioned as a first-class compound antihypertensive drug, particularly effective for patients with mild to moderate primary hypertension and elevated heart rates [4] - The product has shown significant advantages in clinical settings, with a large market potential due to the prevalence of hypertension combined with high heart rates [4] - Likujun tablets are widely used across various medical departments, maintaining a leading market share in the field of leukocyte elevation drugs [5] Research and Development - The company is advancing its new antidepressant JJH201501, which is currently in Phase III clinical trials, showing promising results in extending drug half-life and improving efficacy [6] - The new anti-tumor drug JJH201601 is undergoing clinical trials, demonstrating superior efficacy compared to existing treatments in preclinical models [6] - The company has developed a deuterated drug technology platform, enhancing drug safety and efficacy while reducing dosage requirements [7] Investor Relations - The company is committed to regular profit distribution, with a mid-term dividend plan under consideration for 2024, based on operational performance [6] - In the first quarter of 2024, the company distributed cash dividends totaling 51.10 million CNY [6]

一、基本信息 近日，江苏吉贝尔药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局签发的《化学原料药上市申请批准通知书》，现将相关情况公告如下： 证券代码：688566 证券简称：吉贝尔 公告编号：2024-050 江苏吉贝尔药业股份有限公司 自愿披露关于收到化学原料药上市申请批准 通知书的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1、登记号：Y20220001207 二、药品的相关情况 盐酸洛美沙星，是一种喹诺酮类抗菌药，临床主要用于治疗各种革兰氏阳性 菌和阴性菌引起的急、慢性感染性疾病，是公司产品盐酸洛美沙星滴眼液的主要 原料。公司产品盐酸洛美沙星滴眼液主要用于治疗急、慢性细菌性结膜炎、睑缘 1 2、化学原料药名称：通用名称：盐酸洛美沙星；英文名/拉丁名：Lomefloxacin Hydrochloride 3、化学原料药注册标准编号：YBY70752024 4、包装规格：3kg/桶 5、申请事项：境内生产化学原料药上市申请 6、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合 ...

二、监事会会议审议情况 经与会监事认真审议，以投票表决方式审议通过以下议案： （一）审议通过《公司 2024 年半年度报告及摘要》 证券代码：688566 证券简称：吉贝尔 公告编号：2024-043 江苏吉贝尔药业股份有限公司 第四届监事会第十次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 江苏吉贝尔药业股份有限公司（以下简称"公司"）第四届监事会第十次会 议（以下简称"会议"）于 2024 年 8 月 16 日以书面方式发出通知，于 2024 年 8 月 29 日在公司会议室召开。会议应参加表决监事 3 名，实际参加表决监事 3 名， 会议由监事会主席王正先生主持，符合《中华人民共和国公司法》（以下简称"《公 司法》"）及《江苏吉贝尔药业股份有限公司章程》（以下简称"《公司章程》"）的 有关规定，会议合法有效。 根据《公司法》《中华人民共和国证券法》《公开发行证券的公司信息披露内 容与格式准则第 3 号——半年度报告的内容与格式》《上海证券交易所科创板股 票上市规则》等相关法律、法 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, with a total revenue of RMB 500 million, representing a 25% year-over-year growth[1]. - The company's revenue for the first half of 2024 reached ¥433,661,702.66, representing a 3.55% increase compared to ¥418,811,759.66 in the same period last year[20]. - The net profit attributable to shareholders increased by 26.74% to ¥122,005,971.06 from ¥96,263,228.12 year-on-year[20]. - The net cash flow from operating activities rose by 19.76% to ¥131,187,342.50 compared to ¥109,542,754.94 in the previous year[20]. - The gross profit margin improved to 60%, up from 55% in the previous year, indicating better cost management[1]. - The company's total assets at the end of the reporting period were ¥2,478,277,716.59, a 12.16% increase from ¥2,209,668,213.23 at the end of the previous year[20]. - The basic earnings per share increased by 27.45% to ¥0.65 from ¥0.51 in the same period last year[21]. Research and Development - The company has allocated RMB 100 million for research and development in the upcoming year, focusing on advanced drug delivery systems[1]. - The company's R&D expenditure accounted for 8.15% of its revenue, up from 6.83% in the previous year, indicating a focus on innovation[21]. - Total R&D investment increased by 23.57% year-on-year, amounting to ¥35,340,409.17, with a significant increase in the proportion of capitalized R&D expenses[77]. - The number of R&D personnel has increased to 107, representing 8.26% of the total workforce, up from 6.51% in the previous year[86]. - The company has established a comprehensive new drug research and development system, focusing on patient needs and clinical value, supported by a professional R&D team and various innovative drug development technologies[61]. Product Development and Pipeline - New product development includes the launch of two innovative drug formulations expected to enter the market by Q4 2024[1]. - The company is engaged in the development of innovative drugs targeting depression, tumors, and gastric diseases, expanding its therapeutic areas[25]. - The company is advancing its new antidepressant drug JJH201501, currently in Phase III clinical trials, which shows promising pharmacokinetic properties[38]. - The anti-tumor drug JJH201601, developed using liposome technology, has shown superior anti-tumor effects in preclinical models compared to imported drugs, and is currently undergoing Phase I clinical trials[38]. - The company is also developing products for treating gastric acid-related issues, cholecystitis, and diabetes, expanding its therapeutic portfolio[39]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[1]. - The company has established a comprehensive marketing network covering major regions in China, enhancing its market reach[90]. - The company plans to increase its sales force by 20% to enhance customer engagement and support[1]. - The sales strategy combines academic promotion with pharmaceutical distributors, optimizing marketing strategies to enhance product sales to hospitals and pharmacies[65]. Corporate Governance and Compliance - The company has appointed three new independent directors, effective from May 20, 2024, following the resignation of three independent directors who served their maximum term of six years[123]. - The company has committed to ensuring the authenticity and completeness of its prospectus and will compensate investors for any losses due to false statements or omissions[175]. - The company has established measures to prevent and reduce related party transactions to protect the rights of minority shareholders[178]. - The company has not reported any non-operating fund occupation or guarantee violations during the reporting period[190]. Environmental Responsibility - Environmental protection investments during the reporting period amounted to 2.34251 million yuan[130]. - The company achieved wastewater discharge compliance with maximum concentrations of key pollutants such as ammonia nitrogen at 1.486 mg/L, well below the limit of 35 mg/L[131]. - The company has implemented carbon reduction measures, successfully reducing carbon emissions through source control and energy-efficient equipment[138]. - The company has established dedicated wastewater treatment and exhaust gas processing facilities, which have been operating normally without any significant environmental issues[132]. Future Outlook - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 20% to 30%[1]. - The company is focusing on expanding its product pipeline with new anti-depressant drugs, with an investment of 1,900 million yuan planned[200]. - The company anticipates completing the Phase III clinical trials for JJH201601 by the end of 2028[200]. - The company is committed to improving operational management and internal controls to enhance operational efficiency and profitability[171].